Conditions: Advanced Malignant Solid Tumors
Keywords: HKI-272 Paclitaxel Combination Solid Tumor
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 10
Healthy volunteers: no

Brief summary:
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.

Detailed description:

Arms:
arm 1: Neratinib 160 mg + Paclitaxel 80 mg/m\^2 arm 2: Neratinib 240 mg + Paclitaxel 80 mg/m\^2

Interventions: intervention 1: Neratinib intervention 2: Paclitaxel
Intervention descriptions: intervention 1: Administered orally, continuous, once daily. intervention 2: Administered IV, on days 1, 8, 15 of 28 day cycle.

Protocol document: